Brief: Antengene Corp Says China NMPA Has Approved Phase I Study Of ATG-101 For Treatment Of Advanced Solid Tumors
10/03/2022 01:04
March 10 (Reuters) - Antengene Corporation Ltd 6996.HK :
* CHINA NMPA HAS APPROVED PHASE I STUDY OF ATG-101 FOR
TREATMENT
OF ADVANCED/METASTATIC SOLID TUMORS AND B-CELL NON-HODGKIN
LYMPHOMA
Source text for Eikon: ID:nHKSb9rC2M
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106